Syntec Optics enabling optices for near vision correction

Syntec Optics (OPTX) Holdings is enabling optics for the clinical development of innovative, non-incisional optics-based refractive error correction to recover near vision. This common age-related vision condition, affecting an estimated 128 million people in the U.S. alone, presents a significant and growing market opportunity for effective treatment solutions. The gradual loss of ability to focus on nearby objects is a natural part of aging, typically becoming noticeable in the early to mid-40s and continuing to worsen until around age 65. While traditional solutions include glasses and contact lenses, and surgical options involve incisional methods, Syntec Optics is leveraging its advanced optical manufacturing capabilities to support the development of a less invasive alternative. “We are really glad for this opportunity to get involved early in the development, enabling optics for a product that creates a substantial demand for safer, quicker, effective, and convenient treatment options,” said Matt Carey, head of business development and delivery at Syntec Optics. “We are proud to apply our decades of expertise in designing and manufacturing high-precision optics to support the clinical advancement of non-incisional solutions being developed by our customer. Our ability to produce complex optics is crucial for such innovative medical devices, and we believe this technology has the potential to improve the quality of life for millions significantly.”